MVR C5252
Alternative Names: C-5252; MVR-C5252; T-5 - ImmVira PharmaLatest Information Update: 06 Aug 2024
At a glance
- Originator Immvira Pharma
- Class Antineoplastics; Gene therapies; Immunotherapies; Interleukins; Monoclonal antibodies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunologic cytotoxicity; Interleukin-12 expression stimulants; Programmed cell death 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Glioblastoma; Glioma
Most Recent Events
- 11 Jun 2024 Phase-I clinical trials in Glioma (Second-line therapy or greater) in USA (Intratumoural), (NCT06126744)
- 05 Apr 2024 Adverse events and pharmacodynamics data from the preclinical studies in Glioblastoma presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 29 Mar 2023 National Medical Products Administration (NMPA) recommends approval of MVR C5252 for malignant glioma in China